A Study of Linperlisib Combination With Camrelizumab in Patients With Solid Tumor

Overview

It is a single-arm, open-label, multicenter, phase I trial,aiming at exploring the MTD and RP2D of Linperlisib combination with Camrelizumab in treating patients with advanced solid tumor,observing the preliminary efficacy.

Full Title of Study: “A Single-arm, Open-label, Multicenter,Phase I Study of Linperlisib Combination With Camrelizumab in Patients With Advanced Solid Tumor”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: August 31, 2023

Detailed Description

The trial can be divided into two parts: dose escalation part and dose expansion part. Camrelizumab will be administrated intravenously in a predetermined fixed dose(200mgQ3w)in both parts. In dose escalation part,Linperlisib will be administrated from 40mgQD,60mgQD to 80 mgQD in sequence with the classic "3+3" design.The purposes of this part are figuring out the MTD and RP2D of Linperlisib combination with Camrelizumab in treating patients with advanced solid tumor,and observing the PK characteristics of Linperlisib when using combination with Camrelizumab. When finishing the dose escalation part,one combination dose of Linperlisib with Carelizumab will be selected to be studied on a wider scale of patients with advantage solid tumor in dose expansion part.Purposes of this part are further observing the PK characteristics of Linperlisib when using combination with Camrelizumab,while observing the preliminary efficacy of Linperlisib when using combination with Camrelizumab.

Interventions

  • Drug: Linperlisib Tablet
    • Linperlisib Tablet Oral administration, once a day, for 21 consecutive days as a treatment cycle; Camrelizumab for Injection 200 mg intravenously every 3 weeks. Camrelizumab should be administered prior to Linperlisib.

Arms, Groups and Cohorts

  • Experimental: Linperlisib +Camrelizumab 200mgQ3w
    • Linperlisib will be administrated orally from 40mgQD, 60mgQD to 80mgQD in sequence during dose excalation part and a selected dose in dose expansion part,for 21 consecutive days as a treatment cycle; Camrelizumab will be administrated intravenously 200mg every 3 weeks in all patients just before the administration of Linperlisib.

Clinical Trial Outcome Measures

Primary Measures

  • DLTs
    • Time Frame: At the end of Cycle 1 (each cycle is 21 days)
    • dose limited toxicities
  • TEAEs
    • Time Frame: from day 1after taking the investigational product till 30 days after withdrew from the study
    • treatment emergent adverse events

Secondary Measures

  • Drug exposure
    • Time Frame: At the end of Cycle 1 (each cycle is 21 days)
    • Peak Plasma Concentration (Cmax)
  • PK parameters
    • Time Frame: At the end of Cycle 1 (each cycle is 21 days)
    • Area under the plasma concentration versus time curve (AUC).etc.
  • Effectiveness evaluation index
    • Time Frame: From date of screening until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months
    • ORR、DOR、DCR、TTR、PFS、OS

Participating in This Clinical Trial

Inclusion Criteria

  • 18 years old≦age≦75 years old; – Histologically or cytologically confirmed locally advanced or metastatic malignant solid tumors; – Failure of previous standard treatment (sufficient prior treatment and no better treatment than participating in clinical research); – Qualified basic organ function and body condition; – The expected survival is greater than 3 months; – Adequate washout period. Exclusion Criteria:

  • Prior allergy to study drug components; – Chronic metabolic diseases that are poorly controlled by medication; – Brain metastases, infection, hemorrhage, autoimmune disease or cardiovascular disease, whichever is in active state; – Digestive tract diseases that affect absorption of studied drugs.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Shanghai YingLi Pharmaceutical Co. Ltd.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Li Zhang, Doctor, Principal Investigator, Cancer Hospital affiliated to Sun Yat-sen University
  • Overall Contact(s)
    • Li Zhang, Doctor, 13902282893, zhangli@sysucc.org.cn

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.